Medicinal Cannabis on Prescription in The Netherlands: Statistics for 2003

Medicinal Cannabis on Prescription in The Netherlands: Statistics for 2003–2016

Published:2018-05 Issue:1 Volume:3 Page:54-55
ISSN:2378-8763
Container-title:Cannabis and Cannabinoid Research
language:en
Short-container-title:Cannabis and Cannabinoid Research

Author:

de Hoop Bas¹,Heerdink Eibert R.²³,Hazekamp Arno⁴

Affiliation:

1. Bedrocan International, Veendam, The Netherlands.

2. Department of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

3. Division of Laboratory Medicine & Pharmacy, Department of Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands.

4. Hazekamp Herbal Consulting BV, Leiden, The Netherlands.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Complementary and alternative medicine,Pharmacology

Link

http://www.liebertpub.com/doi/pdf/10.1089/can.2017.0059

Reference2 articles.

1. Cannabis: From Cultivar to Chemovar II—A Metabolomics Approach to Cannabis Classification

2. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of red and white light in optimizing growth and accumulation of plant specialized metabolites at two light intensities in medical cannabis (Cannabis sativa L.);Frontiers in Plant Science;2024-06-18

2. Evaluating possible ‘next day’ impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial;Psychopharmacology;2024-05-17

3. Impact of the use of cannabis as a medicine in pregnancy, on the unborn child: a systematic scoping review protocol;2024-05-14

4. Sociodemographic differences and experienced effects of young adults who use cannabis mainly for self-medication versus recreationally in Finland;Drugs, Habits and Social Policy;2023-08-22

5. Cannabis policy in The Netherlands: Rationale and design of an experiment with a controlled legal (‘closed’) cannabis supply chain;Health Policy;2023-03